Immune privilege or inflammation? Insights into the Fas ligand enigma
- 1 March 2001
- journal article
- Published by Springer Nature in Nature Medicine
- Vol. 7 (3) , 271-274
- https://doi.org/10.1038/85395
Abstract
Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.Keywords
This publication has 35 references indexed in Scilit:
- Interleukin 1 and interleukin 1β converting enzyme (caspase 1) expression in the human colonic epithelial barrier. Caspase 1 downregulation in colon cancerGut, 1999
- Massive acinar cell apoptosis with secondary necrosis, origin of ducts in atrophic lobules and failure to regenerate in cyanohydroxybutene pancreatopathy in ratsInternational Journal of Experimental Pathology, 1999
- Fas/Fas Ligand Interaction in Human Colorectal Hepatic MetastasesThe American Journal of Pathology, 1999
- Depletion of the Natural Killer Cell Population in the Peritoneum by AK-5 Tumor Cells Overexpressing Fas-Ligand: A Mechanism of Immune EvasionCellular Immunology, 1998
- Constitutive Expression of FasL in ThyrocytesScience, 1998
- FAS LIGAND GENE TRANSFER TO RENAL ALLOGRAFTS IN RATSTransplantation, 1998
- Expression of Fas and Fas Ligand and Apoptosis in Tumor-Associated Lymphocytes and in Tumor Cells from Malignant Pleural EffusionsNatural Immunity, 1998
- The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.The Journal of Experimental Medicine, 1996
- Unraveling Immune PrivilegeScience, 1995
- Expression of APO‐1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epitheliumInternational Journal of Cancer, 1994